Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Syndrome X and Endothelial Dysfunction

This study has been terminated.
Sponsor:
Information provided by:
Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT00190086
First received: September 11, 2005
Last updated: NA
Last verified: December 2001
History: No changes posted
  Purpose

Cardiac syndrome X is characterized by angina, positve stress test, and patent coronary angiography, and its probable mechanism is microvascular dysfunction associated with endothelial dysfunction. We used brachial artery flow-mediated vasodilation to assess the endothelial function of the patients with syndrome X, coronary artery disease, and controls. Methods: We enrolled 28 patients with syndrome X, 11 healthy volunteers and 11 coronary artery disease patients. All subjects underwent a 2-step brachial artery flow-related vasodilation test: ultrasound artery diameter was measured at rest and after occlusion to assess endothelium-dependent vasodilation and after sublingual nitroglycerin to determine endothelium-independent condition. Serum endothelin-1 assay was performed for all participants. Results: The cardiac syndrome X patients had lower brachial artery dilation ratio (diameter after test/ diameter before test) than controls (1.10 +/- 0.09 versus 1.27 +/- 0.11, p=0.013), but the ratio is still higher than CAD patients (1.10 +/- 0.09 versus 1.02 +/- 0.07, p<0.001). After sublingual nitroglycerin, all 50 subjects had adequate vasodilation. Besides, normal controls have higher endothelin-1 level than the others.

We concluded that syndrome X patients have worse endothelial function than healthy control, but patients of CAD had even worse endothelium function than cardiac syndrome X patients.

Keywords: Cardiac syndrome X, coronary artery disease, endothelium-dependent vasodilation, endothelium-independent vasodilation, flow-mediated vasodilation, endothelin-1


Condition Phase
Syndrome X
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional

Further study details as provided by Far Eastern Memorial Hospital:

Estimated Enrollment: 28
Study Start Date: January 2001
Estimated Study Completion Date: December 2001
Detailed Description:

Cardiac syndrome x (CSX), which is defined as the combination of typical chest pain, electrocardiography or nuclear medicine evidence suggesting myocardial ischemia, and patent coronary arteriogram, comprises approximately 10-30% of the patients undergoing coronary angiogram.1,2 However, since it was first introduced in 1973, the pathogenesis of CSX has remained an enigma.1, 2 Among all the hypothetic explanations of CSX, including abnormal pain perception and non-cardiogenic origin of pain, the coronary microvascular dysfunction (microvascular angina), which represents reduced microvascular dilatory response and increased resistence, has been consistently found in CSX patients. 2, 3 This microvascular angina is believed to bridge the gap between the ischemic evidence and the normal-looking of coronary tree of CSX, and seems attributed to the endothelium dysfunction (ED), another frequently reported abnormality in CSX.2.3 By definition, ED is characterized by the endothelium-dependent vasodilation (EDVD) impairment, which is believed to be caused by decreased release of NO activity and/or activity, while the endotheliumindependent vasodilation (EIVD) remains preserved. 2,3,4 Therefore, it is asserted that endothelium-dependent dilatation of the resistance coronary arteries is defective in patients with CSX, and such defects may contribute to the altered regulation of myocardial perfusion in these patients.5 On the other hand, ED play a pivotal role in the development, progression, and clinical manifestations of atherosclerosis, as well as in the development of ischemia and thrombosis in the late stages of the disease, by promoting coronary vasoconstriction and thrombosis.4 Instead of using invasively intravascular measuring method used for endothelial function assessment, Celermajer et al first introduced the non-invasive measurement of the flow-mediated vasodilation (FMD) of forearm brachial artery in the assessment of EDVD and EIVD.6 This method was reported to have good correlation to the invasively intravascular studies in coronary systems.4 In this study, we want to compare the difference of forearm FMD, which respond to specially programmed stimuli, in three patient groups: CSX, coronary artery disease (CAD), and normal volunteers. A two-staged stimulation strategy is utilized to assess the EDVD (with cuff occlusion) and EIVD (with sublingual nitroglycerin) consecutively. A baseline plasma endothelin-1 (ET-1) concentration is also checked for each patient enrolled.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • which was performed under the impression of CAD due to positive treadmill electrocardiography test or ischemic evidence on Thallium scan, yielded the result of patent coronary tree. After the confirmation of angina symptoms and double-blinded review of the stress test and angiography result by 2 cardiologists to exclude controversial result

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00190086

Sponsors and Collaborators
Far Eastern Memorial Hospital
Investigators
Principal Investigator: A H Li, MD Far Eastern Memorial Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00190086     History of Changes
Other Study ID Numbers: FEMH-94001
Study First Received: September 11, 2005
Last Updated: September 11, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Syndrome
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on November 25, 2014